Author

Xiaobing Liang

The University of Texas MD Anderson Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Nicholas BlazaniniD· 2 shared Yonathan LissanuiD· 2 shared Eiru KimiD· 1 shared Hira MazhariD· 1 shared Iqbal MahmudiD· 1 shared Lin Tan· 1 shared Manu M. SebastianiD· 1 shared Md QudratullahiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Nicholas BlazaninORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.

Sasikumar Kotagiri, Yawen Wang, Yanyan Han, Xiaobing Liang, Nicholas Blazanin, Hira Mazhar, Manu M. Sebastian, Phuong Kieu Nguyen, Yongying Jiang, Yonathan Lissanu

This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.

Journal of Medicinal Chemistry · Apr 25, 2025Peer-reviewedCancer Biology

Therapeutic modulation of ROCK overcomes metabolic adaptation of cancer cells to OXPHOS inhibition and drives synergistic anti-tumor activity

Nicholas Blazanin, Xiaobing Liang, Iqbal Mahmud, Eiru Kim, Sara Martinez, Lin Tan, Waikin Chan, Nazanin Esmaeili Anvar, Min Jin Ha, Md Qudratullah, Rosalba Minelli, Michael D. Peoples, Philip L. Lorenzi, Traver Hart, Yonathan Lissanu

This study identifies ROCK inhibition as a strategy to overcome metabolic adaptation in cancer cells to OXPHOS inhibition, showing synergistic anti-tumor effects.

bioRxiv · Sep 16, 2024 · PreprintCancer Biology